Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients?
- PDF / 328,409 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 74 Downloads / 215 Views
CLINICAL TRIAL
Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients? Alexandra Jobert 1,2 & Edouard-Jules Laforgue 1,3,4 & Marie Grall-Bronnec 1,4 & Morgane Rousselet 1,3,4 & Morgane Péré 2 & Pascale Jolliet 1,3 & FAN-Network 5 & Fanny Feuillet 1 & Caroline Victorri-Vigneau 1,3 Received: 1 July 2020 / Accepted: 23 September 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Purpose Benzodiazepines (BZDs) and related drugs (Z-drugs) are mainly taken chronically, and older people are much more likely to take them on a chronic basis despite recommendations. Withdrawal symptoms could be an obstacle to stopping BZD/Zdrug administration. The main objective of this study is to estimate the prevalence of withdrawal symptoms in patients aged 65 years and older who have experience a stop of BZD/Z-drug. The secondary objectives are to describe the withdrawal symptoms and identify factors associated. Method This ancillary study was based on a national observational study in patients with chronic BZD/Z-drug consumption. Patients who made at least one BZD/Z-drug stop experience were selected. Withdrawal symptoms are described, and a logistic regression was carried out to identify the variables most associated with withdrawal symptoms. Results In total, 697 patients were selected: 78% experienced at least one withdrawal symptom after a stop administering BZDs or Z-drugs; most of the withdrawal symptoms were psychological disorders. Conclusion Our study identifies a specific population experiencing withdrawal symptoms and who cannot stop administering BZD/ Z-drug. We assume that withdrawal symptoms in patients with chronic use play an essential role in the nonstop use of BZD/Z-drugs. Keywords Benzodiazepine . Chronic use . Older people . Withdrawal symptoms . Z-drug
Introduction This manuscript is an original work that has not been previously published or simultaneously submitted for publication elsewhere. Portions of this study were presented at the Société Française de Pharmacologie et de Thérapeutique annual meeting (Lyon, France, 12– 14 June 2019). * Alexandra Jobert [email protected] 1
Inserm UMR 1246, SPHERE, Methods in Patients-centered outcomes and Health Research, Nantes and Tours University, Nantes, France
2
Direction de la Recherche, Centre Hospitalier Universitaire de Nantes, University Hospital, 5 allée de l’île gloriette, Nantes Cedex, 44093 Nantes, France
3
Pharmacologie clinique, Centre Hospitalier Universitaire de Nantes, University Hospital, Place Alexis Ricordeau, 44093 Nantes, France
4
Addictologie et Psychiatrie de liaison, Centre Hospitalier Universitaire de Nantes, University Hospital, Nantes, 8 hôpital Saint-Jacques 85 rue Saint-Jacques, 44093 Nantes Cedex 1, France
5
French Addictovigilance Network, France, France
Benzodiazepines (BZDs) are extensively used, in its April 2017 report [1], the French National Health Product Agency (ANSM) reported that 13% of the French population consumed BZDs or related dr
Data Loading...
